Fur­ther set­ting the stage for go­ing pub­lic, Vivek Ra­maswamy’s Roivant read­ies a deal to buy up a Vant’s stock — cheap

Vivek Ra­maswamy’s Roivant is in the process of reel­ing back in the chunk of shares it doesn’t al­ready own in its sub­sidiary Im­muno­vant ahead of a planned IPO.

In an SEC fil­ing Mon­day morn­ing, Roivant tipped its hand on its mar­ket in­ten­tions and laid out a plan to buy up the 43% of bad­ly bat­tered Im­muno­vant shares it doesn’t al­ready own.

Those shares $IMVT were wal­loped at the be­gin­ning of Feb­ru­ary when Im­muno­vant an­nounced it was putting its lead drug on a vol­un­tary hold, dri­ving the stock price down by 70% at the lat­est count.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER